Review the Clindamycin / Niacinamide source preparation, its listed specifications and the details your practice should confirm with the pharmacy.
For product identification and informed clinic review. No patient checkout is provided.
Optimal names Clindamycin / Niacinamide with 1.2% / 4% and a 30 g package. Confirm component mapping, clindamycin chemical form and strength basis, full formulation, dosage form and intended route.
Listed package: 30 g. Confirm the complete formulation, ingredient identities, percentage basis, dosage form, labeling and current pharmacy requirements. Source specifications are not application or dosing instructions.
Explore source listing1 source entry. Open the pharmacy to review its listings and confirmation notes.
| Source preparation / review note | Listed amount / specification | Package |
|---|---|---|
| Clindamycin/Niacinamide 1.2%/4%Confirm chemical form, percentage basis and dosage form. Single-ingredient labeling does not validate the combination. | 1.2% / 4% — source sequence | 30 g |
Review the exact product with the responsible pharmacy before submitting an order.
Check the ingredient name and its complete specification.
Review product-specific evidence and regulatory information.
Confirm missing or conflicting fields with the pharmacy.
Any further action depends on the exact product and applicable requirements.
CoreLink does not prescribe or dispense. Reference listings are not offers to supply products.
The treating clinician determines suitability and prescribing. Review the exact preparation’s labeling and pharmacy information.
The catalog does not establish that this is the same formulation as a labeled single-ingredient clindamycin product. A package mass alone does not identify a cream or gel.
Reference labeling for clindamycin phosphate topical gel warns about systemic absorption and potentially severe colitis. That specific gel label does not establish the chemical form, labeling or safety of this two-ingredient source preparation. DailyMed: clindamycin phosphate gel reference labeling
Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness or quality. FDA: compounded drug information
Sources checked October 19, 2026. This page provides product information, not diagnosis, treatment selection, dosing or administration instructions.
No equivalence is established. The source does not identify the clindamycin form or dosage form. Confirm those details and review the exact preparation’s labeling with the pharmacy.
No. A source entry does not establish approval, safety, effectiveness, current availability or eligibility. Review the exact preparation and current requirements with the responsible pharmacy.
No. Ingredient concentration, total content and package volume are separate specifications. This page gives no dosing, preparation or administration instructions.
No. Verify the exact product and its regulatory status. A compounded preparation is not FDA-approved, and a reference to an approved product does not establish equivalence.
A shared ingredient name or numerical value does not establish equivalence. Confirm the complete ingredient form, formulation, route and product labeling.
Ask for the exact ingredient identity, full formulation, strength units, dosage form, route, package, current labeling and applicable requirements. Resolve missing or conflicting information.
No. These pages provide reference information and no patient checkout. Patients should discuss treatment with their treating clinician.
Email info@corelinkpharm.com for platform questions. Contact the responsible pharmacy for preparation-specific information.
Contact CoreLink for account information. Ask the pharmacy about exact product specifications and eligibility.